

Rapid communication

Δ^9 -Tetrahydrocannabinol activates $[Ca^{2+}]_i$ increases partly sensitive to capacitative store refilling

Catalin M. Filipeanu, Dick de Zeeuw, S. Adriaan Nelemans *

Groningen Institute of Drug Research (GIDS), Department of Clinical Pharmacology, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands

Received 7 August 1997; accepted 8 August 1997

Abstract

Δ^9 -Tetrahydrocannabinol induces $[Ca^{2+}]_i$ increases in DDT₁MF-2 smooth muscle cells. Both Ca^{2+} entry and release from intracellular Ca^{2+} stores were concentration dependently activated. The Ca^{2+} entry component contributed most to the increases in $[Ca^{2+}]_i$. Stimulation with Δ^9 -tetrahydrocannabinol after functional downregulation of intracellular Ca^{2+} stores by longterm thapsigargin treatment, still induced a major Ca^{2+} entry and a minor Ca^{2+} release component. Thapsigargin sensitive influx and release were selectively inhibited by the cannabinoid CB₁ receptor antagonist SR141716A. No effects on $[Ca^{2+}]_i$ were obtained after stimulation with the CB₂ receptor agonist palmitoylethanolamide. This study is the first demonstration of (1) Ca^{2+} release from thapsigargin sensitive intracellular stores and capacitative Ca^{2+} entry via CB₁ receptor stimulation and of (2) an additional Δ^9 -tetrahydrocannabinol induced thapsigargin insensitive component, mainly representing Ca^{2+} influx which is neither mediated by CB₁ nor CB₂ receptor stimulation. © 1997 Elsevier Science B.V.

Keywords: Δ^9 -Tetrahydrocannabinol; $[Ca^{2+}]_i$; DDT₁MF-2 cell

Cannabinoid receptors are member of the G-protein coupled receptor family and stimulation was shown to lead to inhibition of adenylate cyclase, activation of inwardly rectifying K⁺ channels and inhibition of voltage dependent Ca^{2+} channels (Felder et al., 1995). In response to neurotransmitters or growth factors many receptors of this family also transduce essential signals for cellular functioning via changes in $[Ca^{2+}]_i$ by activating for instance the phospholipase C cascade. However, to date only a few ambiguous results were reported on $[Ca^{2+}]_i$ after cannabinoid receptor stimulation. Anandamide, an endogenous ligand for the CB₁ receptor subtype increases $[Ca^{2+}]_i$ at concentrations above 10 μ M, probably through a non-receptor mediated mechanism (Felder et al., 1993), while rapid transient elevations of $[Ca^{2+}]_i$ were elicited by the CB₂ receptor agonist 2-arachidonylglycerol. However, these latter transients could be blocked by the specific CB₁ receptor antagonist SR141716A (Sagiura et al., 1996).

To investigate whether cannabinoid receptor stimulation induces receptor mediated changes in Ca^{2+} mobilization from intracellular stores and/or Ca^{2+} entry, we measured

$[Ca^{2+}]_i$ using Fura-2 fluorometry in DDT₁MF-2 smooth muscle cells. These cells are appropriate, since they respond to many different receptor ligands with increases in $[Ca^{2+}]_i$ and do not express voltage-dependent Ca^{2+} channels (Molleman et al., 1991). Cells were loaded with 2 μ M Fura-2 acetoxymethyl ester at 22°C, for 30 min in the dark. Fluorescence was measured at 37°C and $[Ca^{2+}]_i$ calculated as described previously (Sipma et al., 1995). A basal $[Ca^{2+}]_i$ of 148 ± 19 nM ($n = 48$) was found. In contrast to the CB₂ receptor agonist palmitoylethanolamide which failed to induce a change in $[Ca^{2+}]_i$ (148 ± 20 nM; $n = 4$), the non-selective cannabinoid receptor agonist Δ^9 -tetrahydrocannabinol (Felder et al., 1995) produced a concentration-dependent increase in $[Ca^{2+}]_i$ (Fig. 1A, a). The Ca^{2+} response obtained in normal buffer solution consisted of a transient first phase followed by a sustained increase, comparable to responses observed after stimulation of other receptors in DDT₁MF-2 cells (Den Hertog et al., 1992; Sipma et al., 1995). To establish the relative contribution of transient intracellular Ca^{2+} release and sustained Ca^{2+} influx from extracellular space to the $[Ca^{2+}]_i$ change, the experiment was repeated in Ca^{2+} free buffer solution including 1.5 mM EGTA. Δ^9 -Tetrahydrocannabinol released Ca^{2+} from internal stores concentra-

* Corresponding author. e-mail: s.a.nelemans@med.rug.nl




Fig. 1. Δ^9 -Tetrahydrocannabinol effects on $[Ca^{2+}]_i$ in DDT₁MF-2 cells. Panel A: curve (a), changes in total $[Ca^{2+}]_i$ as obtained in normal external medium; curves (b) and (c), influx and release component, respectively. The release component was obtained by measuring maximum values in Ca^{2+} free medium with 1.5 mM EGTA included. The influx component obtained by subtraction the releasable values from the total values. Panel B: Effects obtained after pretreatment of the cells with thapsigargin (1 μ M) for 48 h; curve (d), changes in total $[Ca^{2+}]_i$ as obtained in normal external medium; curve (e), thapsigargin insensitive influx; curve (f) and (g), thapsigargin sensitive influx and release, respectively; curve (h), thapsigargin insensitive release; curves (i) and (j), superimposed curves showing complete inhibition of the thapsigargin sensitive influx and release (f and g) after pretreatment with SR141716A (1 μ M, 1 min). All values were normalized to the maximum total $[Ca^{2+}]_i$ value as obtained with 100 μ M Δ^9 -tetrahydrocannabinol (378 ± 56 nM, $n = 6$). Each symbol represents the mean \pm S.E.M. from at least 4 separate experiments.

tion dependently (Fig. 1A, c). The difference observed between the changes in $[Ca^{2+}]_i$ in the presence and absence of extracellular Ca^{2+} represent a substantial Ca^{2+} influx component (Fig. 1A, b). In accordance readdition of 2.5 mM Ca^{2+} after a Δ^9 -tetrahydrocannabinol (100 μ M) response under extracellular free Ca^{2+} conditions, completely restored the Ca^{2+} entry component ($98 \pm 5\%$; $n = 4$). Surprisingly, the Ca^{2+} release component consisted of two phases: a pronounced transient second phase developed (maximum values reached after 31 ± 3 s; $n = 6$) before the first transient phase was returned to basal values (maximum values reached after 26 ± 3 s; $n = 6$).

To further investigate the nature of these intracellular compartments, Ca^{2+} stores were functional downregulated

by longterm treatment with the endoplasmic reticulum Ca^{2+} -ATPase inhibitor thapsigargin (1 μ M, 48 h; Short et al., 1993). The first phase after Δ^9 -tetrahydrocannabinol stimulation under extracellular Ca^{2+} free conditions was not affected, but the second phase was completely abolished. This indicates the presence of two intracellular Ca^{2+} stores susceptible to stimulation with Δ^9 -tetrahydrocannabinol, one of which is thapsigargin insensitive (Fig. 1B, h) and one thapsigargin sensitive (Fig. 1B, g). Apparently Δ^9 -tetrahydrocannabinol is able to release Ca^{2+} from two distinguishable agonist sensitive Ca^{2+} stores existent in DDT₁MF-2 cells (Den Hertog et al., 1992). Due to down-regulation of the Ca^{2+} stores evidently also the Ca^{2+} entry component is affected. The majority of Ca^{2+} entry is thapsigargin insensitive (Fig. 1B, e) and about 15% is thapsigargin sensitive (Fig. 1B, f), representing the so called store-dependent capacitative Ca^{2+} entry (Putney, 1986).

Pretreatment with the CB₁ receptor antagonist SR141716A (1 μ M, 1 min) did neither affect thapsigargin insensitive Ca^{2+} influx nor Ca^{2+} release (data not shown), but selectively abolished the thapsigargin sensitive Ca^{2+} release and the capacitative Ca^{2+} entry (Fig. 1B, i and j). These results were confirmed by Ca^{2+} readdition experiments in the presence of SR141716A in which Δ^9 -tetrahydrocannabinol (32 μ M) responses were restored to $78 \pm 3\%$ ($n = 6$) compared to control values.

The principle findings of the present study performed in DDT₁MF-2 smooth muscle cells are the first demonstration of (1) Ca^{2+} release from thapsigargin sensitive intracellular stores and capacitative Ca^{2+} entry via CB₁ receptor stimulation and of (2) an additional Δ^9 -tetrahydrocannabinol induced thapsigargin insensitive component, mainly representing Ca^{2+} influx which is neither mediated by CB₁ nor CB₂ receptor stimulation.

Acknowledgements

C.M.F. is a recipient of an Ubbo Emmius Fellowship from the Groningen Utrecht Institute for Drug Exploration (GUIDE).

References

- Den Hertog, A., Hoiting, B., Molleman, A., van den Akker, J., Nelemans, S.A., 1992. Calcium from separate receptor-specific intracellular stores induced by histamine and ATP in a hamster cell line. *J. Physiol. (London)* 454, 591–607.
- Felder, C.C., Briley, E.M., Axelrod, J., Simpson, T., Mackie, K., Devane, W.A., 1993. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. *Proc. Natl. Acad. Sci. USA* 90, 7356–7660.
- Felder, C.C., Kelly, E.J., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., Lai, Y., Ma, A.L., Mitchell, R., 1995. Comparison of the pharmacology and signal transduction of human cannabinoid CB1 and CB2 receptors. *Mol. Pharmacol.* 48, 443–450.

- Molleman, A., Hoiting, B., Duin, M., van den Akker, J., Nelemans, A., Den Hertog, A., 1991. Voltage dependent sodium and potassium, but not calcium conductances in DDT₁ MF-2 smooth muscle cells. *Pfluegers Arch. Eur. J. Physiol.* 417, 479–484.
- Putney, J.W. Jr., 1986. A model for receptor-regulated calcium entry. *Cell Calcium* 7, 1–12.
- Sagiura, T., Kodaka, T., Kondo, S., Tonegawa, T., Nakane, S., Kishimoto, S., Yamashita, A., Waku, K., 1996. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid transient elevation of intracellular free Ca²⁺ in neuroblastoma×glioma hybrid NG108-15 cells. *Biochem. Biophys. Res. Commun.* 229, 58–64.
- Short, A.D., Bian, J., Ghosh, T.K., Waldron, R.T., Rybak, S.L., Gill, D.L., 1993. Intracellular Ca²⁺ pool content is linked to control of cell growth. *Proc. Natl. Acad. Sci. USA* 90, 4986–4990.
- Sipma, H., Duin, M., Hoiting, B., den Hertog, A., Nelemans, A., 1995. Regulation of histamine- and UTP-induced increases in Ins(1,4,5)P₃, Ins(1,3,4,5)P₄ and Ca²⁺ by cyclic AMP in DDT₁ MF-2 cells. *Br. J. Pharmacol.* 114, 383–390.